NZ811397A - Liquid tasimelteon formulations and methods of use thereof - Google Patents

Liquid tasimelteon formulations and methods of use thereof

Info

Publication number
NZ811397A
NZ811397A NZ811397A NZ81139720A NZ811397A NZ 811397 A NZ811397 A NZ 811397A NZ 811397 A NZ811397 A NZ 811397A NZ 81139720 A NZ81139720 A NZ 81139720A NZ 811397 A NZ811397 A NZ 811397A
Authority
NZ
New Zealand
Prior art keywords
tasimelteon
methods
liquid
formulations
daily
Prior art date
Application number
NZ811397A
Other languages
English (en)
Inventor
Deepak Phadke
Mihael Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73856392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ811397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority claimed from NZ789270A external-priority patent/NZ789270B2/en
Publication of NZ811397A publication Critical patent/NZ811397A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NZ811397A 2019-12-13 2020-12-11 Liquid tasimelteon formulations and methods of use thereof NZ811397A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962947774P 2019-12-13 2019-12-13
US202062972902P 2020-02-11 2020-02-11
US202063119488P 2020-11-30 2020-11-30
NZ789270A NZ789270B2 (en) 2020-12-11 Liquid tasimelteon formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ811397A true NZ811397A (en) 2025-11-28

Family

ID=73856392

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ811397A NZ811397A (en) 2019-12-13 2020-12-11 Liquid tasimelteon formulations and methods of use thereof

Country Status (14)

Country Link
US (5) US11202770B2 (enExample)
EP (1) EP4072542A1 (enExample)
JP (3) JP7503632B2 (enExample)
KR (1) KR102650321B1 (enExample)
CN (1) CN114727978A (enExample)
AU (3) AU2020400065B2 (enExample)
CA (1) CA3161975A1 (enExample)
CL (1) CL2022001546A1 (enExample)
CO (1) CO2022009691A2 (enExample)
IL (2) IL292492A (enExample)
MX (2) MX2022006577A (enExample)
NZ (1) NZ811397A (enExample)
WO (1) WO2021119456A1 (enExample)
ZA (1) ZA202207188B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
AU2022345260A1 (en) 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients
WO2024258786A1 (en) 2023-06-12 2024-12-19 Vanda Pharmaceuticals Inc. Tasimelteon for use in the treatment of delayed sleep-wake phase disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
CN106542973B (zh) * 2015-09-16 2019-06-25 南京华威医药科技集团有限公司 他司美琼中间体及其制备方法
WO2017059877A1 (en) 2015-10-07 2017-04-13 Rontis Hellas S.A. Pharmaceutical composition containing agomelatine and process for the preparation thereof
US9944616B2 (en) * 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
US12447141B2 (en) 2025-10-21
JP2024084859A (ja) 2024-06-25
US20260007633A1 (en) 2026-01-08
US11759446B2 (en) 2023-09-19
JP7503632B2 (ja) 2024-06-20
US11202770B2 (en) 2021-12-21
MX2026003536A (es) 2026-05-04
US20210177799A1 (en) 2021-06-17
CL2022001546A1 (es) 2023-02-24
MX2022006577A (es) 2022-07-04
US20250090492A1 (en) 2025-03-20
AU2026202446A1 (en) 2026-04-23
CN114727978A (zh) 2022-07-08
JP2026117039A (ja) 2026-07-14
JP7875899B2 (ja) 2026-06-18
AU2025205489B2 (en) 2026-01-29
KR102650321B1 (ko) 2024-03-21
CO2022009691A2 (es) 2022-07-29
US12440470B2 (en) 2025-10-14
WO2021119456A1 (en) 2021-06-17
AU2025205489A1 (en) 2025-08-14
AU2020400065B2 (en) 2025-08-14
EP4072542A1 (en) 2022-10-19
JP2023506225A (ja) 2023-02-15
US20210212980A1 (en) 2021-07-15
AU2020400065A1 (en) 2022-06-30
IL292492A (en) 2022-06-01
NZ811345A (en) 2025-07-25
KR20220113983A (ko) 2022-08-17
ZA202207188B (en) 2022-08-31
US20230372285A1 (en) 2023-11-23
IL317244A (en) 2025-01-01
NZ789270A (en) 2024-07-05
CA3161975A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2025003080A (es) Conjugados de il-15, y sus usos
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MY205512A (en) Arginase inhibitors
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MY207121A (en) Anti-ror antibody constructs
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2022000712A (es) Moduladores de nlrp3.
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
MX2025004864A (es) Compuestos que median la degradacion de proteinas y metodos de uso de los mismos
WO2021004958A3 (en) Compositions comprising bacterial strains
MX2021013602A (es) Inhibidores de jak.

Legal Events

Date Code Title Description
PSEA Patent sealed